Source: Health Products Regulatory Authority (ZA) Revision Year: 2022 Publisher: Ranbaxy Pharmaceuticals (Pty) Ltd, 14 Lautre Road, Stormill, Ext. 1, Roodepoort, 1724, South Africa
Flucoric 50 Capsules.
Flucoric 100 Capsules.
Flucoric 150 Capsules.
Flucoric 200 Capsules.
| Pharmaceutical Form |
|---|
|
Capsule. Flucoric 50 Capsules: Blue/white hard gelatin, self locked capsules of size ‘4’ imprinted with ‘RANBAXY’ in black edible ink on both cap and body containing white to off-white powder. Flucoric 100 Capsules: Blue/white hard gelatin, self locked capsules of size ‘2’ imprinted with ‘RANBAXY’ in black edible ink on both cap and body containing white to off-white powder. Flucoric 150 Capsules: Blue/blue hard gelatin, self locked capsules of size ‘1’ imprinted with ‘RANBAXY’ in black edible ink on both cap and body containing white to off-white powder. Flucoric 200 Capsules: Purple/white hard gelatin, self locked capsules of size ‘0’ imprinted with ‘RANBAXY’ in black edible ink on both cap and body containing white to off-white powder. |
Each capsule contains fluconazole 50 mg.
Contains sugar: lactose monohydrate 38,5 mg per capsule.
Each capsule contains fluconazole 100 mg.
Contains sugar: lactose monohydrate 77,5 mg per capsule.
Each capsule contains fluconazole 150 mg.
Contains sugar: lactose monohydrate 115,5 mg per capsule.
Each capsule contains fluconazole 200 mg.
Contains sugar: lactose monohydrate 154 mg per capsule.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Fluconazole |
Fluconazole is a triazole antifungal agent. Its primary mode of action is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. |
| List of Excipients |
|---|
|
Flucoric Capsules: colloidal anhydrous silica Capsule shell – cap (Blue, opaque) – Flucoric 50/100/150 Capsules): Patent Blue (Cl No. 42051) - (Flucoric 50/100/150 Capsules) Capsule shell – cap Purple, opaque (Flucoric 200 Capsules): Patent Blue (Cl No. 42051) Capsule Body (White, opaque) Flucoric 50/100/200 Capsules): Titanium dioxide (Cl No. 77891) Capsule Body (Blue, opaque) - (Flucoric 150 Capsules): Patent Blue (Cl No. 42051) Composition of the printing ink (Flucoric 50/100/150/200 Capsules): Shell USNF |
Flucoric 50 Capsules: Cartons containing blister strips consisting of white, opaque PVC (PVdC coated) film with an aluminium foil backing containing 14 capsules each.
Flucoric 100 Capsules: Cartons containing blister strips consisting of white, opaque PVC (PVdC coated) film with an aluminium foil backing containing 14 capsules each.
Flucoric 150 Capsules: Cartons containing blister strips consisting of white, opaque PVC (PVdC coated) film with an aluminium foil backing containing 1 or 4 capsules each.
Flucoric 200 Capsules: Cartons containing blister strips consisting of white, opaque PVC (PVdC coated) film with an aluminium foil backing containing 28 capsules each.
Ranbaxy Pharmaceuticals (Pty) Ltd, 14 Lautre Road, Stormill, Ext. 1, Roodepoort, 1724, South Africa
Flucoric 50 Capsules: 37/20.2.2/0114
Flucoric 100 Capsules: 37/20.2.2/0115
Flucoric 150 Capsules: 37/20.2.2/0116
Flucoric 200 Capsules: 37/20.2.2/0117
05 September 2003
| Drug | Countries | |
|---|---|---|
| FLUCORIC | Lithuania, Romania, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
